QSAR - {SPAM?} Top 10 Biotech Companies 2004: Innovators and Leaders in the Market

> Top 10 Biotech Companies 2004: Innovators and Leaders in the Market
> New visiongain report
>
> More than 325 million people worldwide have been helped by the more than 130 biotechnology drugs and vaccines approved by the US FDA. Of the biotech medicines on the market, 70 per cent were approved in the last six years.
>
> Market capitalization of the biotech industry was $224 billion in 2002 and the industry has more than tripled in size since 1992, with revenues increasing from $8 billion in 1992 to $27.6 billion in 2001. Biotechnology is one of the most research-intensive industries in the world. The U.S. biotech industry spent $15.6 billion on research and development in 2001.
>
> The life sciences hold considerable promise as an investment sector. In recent years biotech has established itself as a successful industry in its own right, with a number of high profile approvals by leading companies contributing to the profile of the industry.
>
> Visiongain> '> s Top 10 Biotech Companies 2004 assesses the impact of the leading companies in this industry. Included in this report is detailed information concerning various facets of the companies> '> business, highlighting their reasons for success in the marketplace. The following information is provided:
>
> *> Key product sales and forecasts
> *> Research and development highlights
> *> Reasons for Success
> *> Key licensing agreements
> *> Total revenue
> *> Royalties and licensing revenue
> *> Operating expenses
> *> Research and development expenses
> *> Merger/acquisition status
> *> Total assets
>
> Other key financial figures and company background information are also provided.
>
> From the standpoint of growth of Earnings Per Share (EPS), the leading five biotechs outperformed the leading five pharmaceutical companies. When we take into account the fact that the future of the global pharmaceutical industry is suffering from a developmental 'dry spell' where their product pipelines are concerned, the role of biotech is becoming increasingly prominent in their future. This report provides valuable information and analysis for biotech companies, pharma leaders, and venture capitalists who wish to benchmark the leaders in the field and better understand why some companies succeed and some fail. Order this report today.
>
> Below are the full table of contents:
>
> Table of Contents - Top 10 Biotech Companies 2004: Innovators and Leaders in the Market
>
> 1 Introduction and Methodology
> 1.1 The State of the Biotechnology Industry in 2003
> 1.2 Some Important Facts About the Biotechnology Industry
> Table 1.1 The Rise of the Biotech Industry: Revenue and R&D 1992-2001
> Graph 1.1 Biopharmaceutical Sales Growth 1992-2001
> Graph 1.2 New Biotech Drug Approvals 1992-2001
> 1.3 The Rise of Biotechnology in the 20th Century: A Timeline
> 1.4 Valuing the Biotech Market in 2003
> Graph 1.3 Average Value of Biotech Alliance by Developmental Stage
> Table 1.2 Average Value of Biotech Alliance by Developmental Stage
> Graph 1.4 Investment in US Life Sciences 1995 - 2002
> Table 1.3 Investment in US Life Sciences 1995 - 2002
> 1.5 Report Format
> 1.6 Research Methodology
>
> 2 Amgen
> 2.1 Overview of Business
> 2.2 Corporate History
> 2.3 Employees
> 2.4 Headquarters and Year Established
> 2.5 U.S. Exchange Ticker Symbol
> 2.6 Historical Stock Prices
> Graph 2.1 Amgen> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 2.7 Key Financial Information
> 2.7.1 Product Sales
> Graph 2.2 Amgen Product Sales 1999-2002
> 2.7.2 Corporate Partner Revenues
> Graph 2.3 Amgen Corporate Partner Revenues 2000-2002
> 2.7.3 Royalty Income
> Graph 2.4 Amgen Royalty Revenues 2000-2002
> 2.7.4 Revenues
> Graph 2.5 Amgen Revenues 1999-2002
> Table 2.1 Total Amgen Revenues, by Geographic Region 2000-2002
> Graph 2.6 Total Amgen Revenues, by Geographic Region 2002
> 2.7.5 Total Operating Expenses>
> 2.7.6 Research and Development Expenses
> 2.7.7 Assets
> Graph 2.7 Amgen Total Assets 2000-2002
> 2.7.8 Net Income/Net Loss
> Graph 2.8 Amgen Adjusted Net Income 1999-2002
> 2.7.9 Stockholders' Equity
> 2.7.10 Earnings/Loss per Share
> 2.8 The Acquisition of Immunex and it's Ramifications
> Table 2.2 Peak Revenues Forecast for Enbrel 2002-2005
> Graph 2.9 Peak Revenues for Amgen's Enbrel 2002-2005
> 2.9 Key Therapeutic Areas
> 2.10 Leading Prescription Drug Products in the Amgen Portfolio
> Graph 2.10 Amgen's Share of the Biopharmaceutical Market 2002
> 2.10.1 Epogen
> Graph 2.11 Global Sales of Epogen 2000-2002
> 2.10.2 Aranesp
> Graph 2.12 Global Sales of Aranesp 2001-2002
> 2.10.3 Neulasta
> 2.10.4 Neupogen
> Graph 2.13 Global Sales of Neupogen 2000-2002
> 2.10.5 Enbrel
> 2.11 Joint Ventures/Alliances
> 2.11.1 Royalties
> 2.12 Research and Development
> 2.12.1 Highlights
> Graph 2.14 Amgen R & D Expenses 1999-2002
> Table 2.3 Amgen's Hematology and Oncology Pipeline
> Table 2.4 Amgen's Bone and Inflammation Pipeline
> Table 2.5 Amgen's Neurology and Endocrinology Pipeline
> 2.13 Reasons for Success
>
> 3 Genentech
> 3.1 Overview of Business
> 3.2 Corporate History
> 3.3 Employees
> 3.4 Headquarters and Year Established
> 3.5 U.S. Exchange Ticker Symbol
> 3.6 Historical Stock Prices
> Graph 3.1 Genentech> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 3.7 Key Financial Information
> 3.7.1 Product Sales
> Graph 3.2 Genentech's Product Sales 2000-2002
> 3.7.2 Corporate Partner Revenues
> Graph 3.3 Genentech's Collaborative Profit Sharing 2000-2002
> 3.7.3 Royalty Income
> Graph 3.4 Genentech's Royalties Income 2000-2002
> 3.7.4 Revenues
> Graph 3.5 Genentech's Total Revenues 2000-2002
> 3.7.5 Total Operating Expenses
> Graph 3.6 Genentech's Total Costs and Expenses 2000-2002
> 3.7.6 Research and Development Expenses
> Graph 3.7 Genentech's Research and Development Expenses 2000-2002
> Graph 3.8 Genentech's R&D Expense as a percentage of revenue 2000-2002
> 3.7.7 Assets
> Graph 3.9 Genentech's Total Assets 2000-2002
> 3.7.8 Net Income (Loss)
> Graph 3.10 Genentech's Net Income (Loss) 2000-2002
> 3.7.9 Stockholders' Equity
> 3.7.10 Earnings/Loss per Share
> 3.8 Key Therapeutic Areas
> 3.8.1 Oncology
> 3.8.2 Immunology
> Graph 3.11 Financial Forecast for Genentech's Immunology Portfolio 2004-2009
> 3.8.3 Vascular Medicine
> 3.8.4 Growth Hormone Products
> 3.9 Leading Prescription Drug Products in the Genentech Portfolio
> Table 3.1 Genentech's Product Sales 2000-2002 ($ mn)
> Graph 3.12 Genentech's Total Product Sales 2000-2002
> Table 3.2 Genentech's Product Sales 2002-2003 (through 3rd Quarter)
> 3.9.1 Rituxan
> Table 3.3 Genentech> '> s Global Sales of Rituxan 2000-2003
> Graph 3.13 Genentech> '> s Global Sales of Rituxan 2000-2003
> 3.9.2 Herceptin
> Graph 3.14 Genentech> '> s Global Sales of Herceptin 2000-2002
> 3.9.3 Growth Hormone Products
> Graph 3.15 Genentech> '> s Global Sales of Growth Hormone Products 2000-2003
> 3.9.4 Thrombolytics
> 3.10 Joint Ventures/Alliances
> 3.11 Research and Development
> Table 3.4 Genentech> '> s Oncology Pipeline
> Table 3.5 Genentech> '> s Immunology Pipeline
> Table 3.6 Genentech> '> s Vascular Medicine Pipeline
> Table 3.7 Other Drugs in Genentech> '> s Pipeline
> 3.11.1 Highlights
> 3.12 Reasons for Success
>
> 4 Biogen Idec
> 4.1 Overview of Business
> 4.2 Corporate Histories
> 4.3 Employees
> 4.4 Headquarters and Year Established
> 4.5 U.S. Exchange Ticker Symbol
> 4.6 Historical Stock Prices
> Graph 4.1 Biogen Idec> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 4.7 Key Financial Information
> 4.7.1 Product Sales
> Graph 4.2 Biogen> '> s Product Sales 1998-2002
> Table 4.1 Idec> '> s Product Sales 1998-2002
> 4.7.2 Corporate Partner Revenues
> Graph 4.3 Idec> '> s Revenues from Unconsolidated Joint Business Arrangements 1998-2002
> 4.7.3 Royalty Income
> Graph 4.4 Biogen> '> s Royalty Revenues 2000-2002>
> 4.7.4 Total Revenues
> Graph 4.5 Biogen> '> s Total Revenues 1998-2002
> Graph 4.6 Idec> '> s Total Revenues 1998-2002
> 4.7.5 Total Operating Expenses
> Graph 4.7 Biogen> '> s Total Costs and Expenses 2000-2002
> Graph 4.8 Idec> '> s Total Costs and Expenses 2000-2002
> 4.7.6 Research and Development Expenses
> Graph 4.9 Biogen> '> s Research and Development Expenses 2000-2002
> Graph 4.10 Idec> '> s Research and Development Expenses 1998-2002
> 4.7.7 Assets
> Table 4.2 Biogen Idec> '> s Total Current Assets 2002-2003
> 4.7.8 Net Income (Loss)
> Graph 4.11 Biogen> '> s Net Income 2000-2002
> Graph 4.12 Idec> '> s Net Income 1998-2002
> 4.7.9 Stockholders' Equity
> 4.7.10 Earnings/Loss per Share
> 4.8 Key Therapeutic Areas
> 4.8.1 Oncology
> 4.8.2 Immunology
> 4.9 Leading Prescription Drug Products in the Biogen IDEC Portfolio
> 4.9.1 Avonex
> 4.9.1.1 Revenues
> 4.9.1.2 Market Competition
> Graph 4.13 Multiple Sclerosis Therapy Market Share Leaders 2002-2003
> Graph 4.14 Anticipated Market Share for MS Therapies 2003
> Table 4.3 Future Sales of Avonex
> 4.9.2 Amevive
> 4.9.2.1 Clinical Efficacy
> 4.9.2.2 Market Entrance and Competition
> 4.9.2.3 Revenues
> 4.9.2.4 Amevive's First Year on the Market: Did it Meet Expectations
> 4.9.2.5 Amevive's Troubles in Europe
> 4.9.2.6 The Future Value of Amevive
> Table 4.4 Projected Sales of Amevive 2003-2009
> Graph 4.15 Future Sales of Amevive
> 4.9.3 Rituxan
> Graph 4.16 Global Sales of Rituxan 1998-2007
> Table 4.5 Revenue from Unconsolidated Joint Business Arrangements
> 4.9.4 Zevalin
> Table 4.6 Global Sales of Zevalin 2002-2003
> 4.10 Joint Ventures/Alliances
> 4.10.1 Royalties
> 4.11 Research and Development
> Table 4.7 Biogen Idec> '> s Oncology Pipeline
> Table 4.8 Biogen Idec> '> s Immunology Pipeline
> 4.11.1 Highlights
> 4.12 Reasons for Success
>
> 5 Serono
> 5.1 Overview of Business
> 5.2 Employees
> 5.3 Headquarters and Year Established
> 5.4 U.S. Exchange Ticker Symbol
> 5.5 Historical Stock Prices
> Graph 5.1 Serono> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 5.6 Key Financial Information
> 5.6.1 Product Sales
> Graph 5.2 Serono> '> s Global Product Sales 1998-2002
> Graph 5.3 Serono> '> s Global Product Sales, by Region 2002
> 5.6.2 Royalty and License Income
> Graph 5.4 Serono> '> s Royalty and License Income 1998-2002
> 5.6.3 Total Revenues
> Graph 5.5 Serono> '> s Total Revenues 1998-2002
> 5.6.4 Total Operating Expenses
> Graph 5.6 Serono> '> s Operating Expenses 1998-2002
> 5.6.5 Research and Development Expenses
> Graph 5.7 Serono> '> s Research and Development Expenses 1998-2002
> 5.6.6 Assets
> Graph 5.8 Serono> '> s Total Assets 1998-2002
> 5.6.7 Net Income (Loss)
> Graph 5.9 Serono> '> s Net Income 1998-2002
> 5.6.8 Stockholders' Equity
> Graph 5.10 Serono> '> s Stockholders> '> Equity 1998-2002
> 5.6.9 Earnings/Loss per Share
> Graph 5.11 Serono> '> s Earnings (Loss) per Share 1998-2002
> 5.7 Key Therapeutic Areas
> 5.7.1 Reproductive Health
> Graph 5.12 Serono> '> s Global Sales of Reproductive Health Products 2000-2002
> 5.7.2 Neurology
> Graph 5.13 Serono> '> s Global Sales of Neurological Products 2000-2002
> 5.7.3 Growth and Metabolism
> Graph 5.14 Serono> '> s Global Sales of Growth and Metabolism Products 2000-2002
> 5.8 Leading Prescription Drug Products in the Serono Portfolio
> 5.8.1 Gonal-F
> 5.8.1.1 Clinical Efficacy
> 5.8.1.2 Revenues
> Table 5.1 Serono> '> s Global Sales of Gonal-F 2001-2003
> Graph 5.15 Serono> '> s Global Sales of Gonal-F 2001-2003
> 5.8.1.3 Market Competition
> Graph 5.16 Infertility Agents World Market Share 2002
> 5.8.2 Rebif
> 5.8.2.1 Clinical Efficacy
> 5.8.2.2 Market Entrance and Competition
> 5.8.2.3 Revenues
> Graph 5.17 The Future Value of Rebif Worldwide 2002-2009
> 5.9 Joint Ventures/Alliances
> 5.9.1 Royalties
> 5.10 Research and Development
> Table 5.18 Serono> '> s Reproductive Health Pipeline
> Table 5.19 Serono> '> s Neurology Pipeline
> Table 5.20 Serono> '> s Autoimmune Disease
> Table 5.21 Serono> '> s Metabolic Pipeline>
> Table 5.22 Serono> '> s Psoriasis Pipeline
> 5.10.1 Highlights
> 5.10.1.1 Raptiva
> 5.10.1.2 Cladribine
> 5.10.1.3 Onercept
> 5.10.1.4 Breaker Peptides
> 5.11 Reasons for Success
>
> 6 Genzyme
> 6.1 Overview of Business
> 6.2 Corporate History Timeline
> 6.3 Employees
> 6.4 Headquarters and Year Established
> 6.5 U.S. Exchange Ticker Symbol
> 6.6 Historical Stock Prices
> Graph 6.1 Genzyme> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 6.7 Key Financial Information
> 6.7.1 Product Sales
> Graph 6.2 Genzyme> '> s Global Product Sales 1998-2002
> 6.7.2 Total Revenues
> Graph 6.3 Genzyme> '> s Total Revenue 1998-2002
> 6.7.3 Total Operating Expenses
> Graph 6.4 Genzyme> '> s Operating Costs and Expenses 2000-2002
> 6.7.4 Research and Development Expenses
> Graph 6.5 Genzyme> '> s Research and Development Expenses 2000-2002
> 6.7.5 Assets
> 6.7.6 Net Income (Loss)
> 6.7.7 Stockholders' Equity
> 6.7.8 Earnings/Loss per Share
> 6.8 Key Product Areas
> 6.8.1 Genzyme General
> Graph 6.6 Genzyme General> '> s Total Revenue 2000-2002
> 6.8.1.1 Therapeutics
> Table 6.1 Genzyme> '> s Therapeutic Products
> Graph 6.7 Genzyme> '> s Therapeutic Sales 2000-2002
> 6.8.1.2 Renal
> Graph 6.8 Genzyme> '> s Renal Product Sales 2000-2002
> 6.8.1.3 Diagnostic Products
> Graph 6.9 Genzyme> '> s Sales of Diagnostic Products 2000-2002
> 6.8.2 Genzyme Biosurgery
> Graph 6.10 Genzyme> '> s Biosurgery Sales 2000-2002
> 6.8.2.1 Orthopaedics
> Graph 6.11 Genzyme> '> s Orthopaedics Sales 2000-2002
> Table 6.2 Genzyme> '> s Biosurgical Specialty Products
> Graph 6.12 Genzyme> '> s Sales of Biosurgical Specialty Products 2000-2002
> 6.8.2.2 Biosurgical Specialties
> 6.8.2.3 Cardiothoracic
> Graph 6.13 Genzyme> '> s Sales of Cardiothoracic Products 2000-2002
> 6.9 Leading Prescription Drug Products in the Genzyme Portfolio
> 6.9.1 Cerezyme Enzyme
> Graph 6.14 Sales of Cerezyme Enzyme 2000-2002
> 6.9.1.1 Clinical Efficacy
> 6.9.1.2 Revenues
> 6.9.1.3 Market Competition
> 6.9.2 Renal Drugs
> 6.9.2.1 Clinical Efficacy
> 6.9.2.2 Revenues
> 6.9.3 Genzyme Biosurgery
> 6.10 The SangStat Acquisition
> 6.11 Select Research and Development Projects
> Table 6.3 Genzyme> '> s Pipeline for Lysosomal Storage Disorders
> Table 6.4 Genzyme> '> s Endocrinology Pipeline
> Table 6.5 Genzyme> '> s Immune-Mediated Diseases Pipeline
> Table 6.6 Genzyme> '> s Orthopaedics Pipeline
> Table 6.7 Genzyme> '> s Cardiovascular Pipeline
> Table 6.8 Genzyme> '> s Cancer Vaccine Pipeline
> 6.11.1 Highlights
> 6.12 Reasons for Success
>
> 7 Chiron
> 7.1 Overview of Business
> 7.2 Corporate History Timeline
> 7.3 Employees
> 7.4 Headquarters and Year Established
> 7.5 U.S. Exchange Ticker Symbol
> 7.6 Historical Stock Prices
> Graph 7.1 Chiron> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 7.7 Key Financial Information
> 7.7.1 Product Sales
> Graph 7.2 Chiron> '> s Product Sales 2000-2002
> 7.7.2 Collaborative Agreement Revenue
> Graph 7.3 Chiron> '> s Collaborative Agreement Revenue 2000-2002
> 7.7.3 Royalty and License Income
> Graph 7.4 Chiron> '> s Royalty and License Revenue 2000-2002
> 7.7.4 Total Revenues
> Graph 7.5 Chiron> '> s Total Revenue 1998-2002
> 7.7.5 Total Operating Expenses
> Graph 7.6 Chiron> '> s Total Operating Expenses 2000-2002
> 7.7.6 Research and Development Expenses
> Graph 7.7 Chiron> '> s Research and Development Expenses 2000-2002
> 7.7.7 Assets
> Graph 7.8 Chiron> '> s Total Assets 1998-2002
> 7.7.8 Net Income (Loss)
> Graph 7.9 Chiron> '> s Net Income 2000-2002
> 7.7.9 Stockholders' Equity
> 7.7.10 Earnings/Loss per Share
> 7.8 Chiron's Businesses
> Graph 7.10 Chiron> '> s Total Product Revenue, by Business
> 7.8.1 Biopharmaceuticals
> Graph 7.11 Chiron> '> s Worldwide Sales of Biopharmaceuticals 2000-2002
> 7.8.2 Vaccines
> Graph 7.12 Chiron> '> s Vaccine Revenue, by Type 2002
> Graph 7.13 Chiron> '> s Vaccine Sales 2000-2002
> 7.8.3 Blood Testing
> Graph 7.14 Chiron> '> s Blood Testing Segment Revenues 2000-2002>
> 7.9 Leading Prescription Drug Products in the Chiron Portfolio
> 7.9.1 Betaseron
> 7.9.1.1 New Formulation for Betaseron
> 7.9.1.2 Clinical Efficacy
> 7.9.1.3 Revenues
> Graph 7.15 Chiron> '> s Sales of Betaseron 2000-2002
> 7.9.1.4 Market Competition
> Graph 7.16 The Future of the Multiple Sclerosis Market 2002-2009
> 7.9.2 Other Products Sales
> 7.9.2.1 TOBI
> 7.9.2.2 Proleukin
> 7.10 Joint Ventures/Alliances
> 7.11 Research and Development
> Table 7.1 Chiron> '> s Biopharmaceutical Pipeline
> Table 7.2 Chiron> '> s Vaccine Pipeline
> Table 7.3 Chiron> '> s Blood Testing Pipeline
> 7.11.1 Highlights
> 7.11.1.1 Proleukin
> 7.11.1.2 HIV Vaccine
> 7.12 Reasons for Success
>
> 8 MedImmune
> 8.1 Overview of Business
> 8.2 Corporate History Timeline
> 8.3 Employees
> 8.4 Headquarters and Year Established
> 8.5 U.S. Exchange Ticker Symbol
> 8.6 Historical Stock Prices
> Graph 8.1 MedImmune> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 8.7 Key Financial Information
> 8.7.1 Product Sales
> Graph 8.2 MedImmune> '> s Total Product Sales 2001-2002
> 8.7.2 Total Revenues
> Graph 8.3 MedImmune> '> s Total Revenue 1998-2002
> 8.7.3 Total Operating Expenses
> Graph 8.4 MedImmune> '> s Total Operating Expenses 2000-2002
> 8.7.4 Research and Development Expenses
> Graph 8.5 MedImmune> '> s Research and Development Expenses 2000-2002
> 8.7.5 Assets
> Graph 8.6 MedImmune> '> s Total Assets 1998-2002
> 8.7.6 Net Income (Loss)
> Graph 8.7 MedImmune> '> s Net Earnings 1998-2002
> 8.7.7 Stockholders' Equity
> Graph 8.8 MedImmune> '> s Stockholders> '> Equity 1998-2002
> 8.7.8 Earnings/Loss per Share
> 8.8 MedImmune's Marketed Products
> 8.8.1 Synagis
> 8.8.1.1 Clinical Efficacy
> 8.8.1.2 Revenues
> Graph 8.9 MedImmune> '> s Sales of Synagis 2001-2002
> 8.8.1.3 Market Competition
> 8.8.2 FluMist
> 8.8.2.1 Revenue
> 8.8.3 Ethyol
> Graph 8.10 MedImmune> '> s Sales of Ethyol 2001-2002
> Table 8.1 MedImmune> '> s Pharmaceutical Pipeline
> 8.8.4 CytoGam
> 8.8.5 NeuTrexin
> 8.8.6 RespiGam
> 8.9 Joint Ventures/Alliances/Royalties
> 8.10 Research and Development
> 8.10.1 Highlights
> 8.11 Reasons for Success
>
> 9 Cephalon
> 9.1 Overview of Business
> 9.2 Employees
> 9.3 Headquarters and Year Established
> 9.4 U.S. Exchange Ticker Symbol
> 9.5 Historical Stock Prices
> Graph 9.1 Cephalon> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 9.6 Key Financial Information
> 9.6.1 Product Sales
> Graph 9.2 Cephalon> '> s Product Sales 1999-2002
> 9.6.2 Collaborative Agreement Revenue
> Graph 9.3 Cephalon> '> s Collaborative Agreement Revenue 1999-2002
> 9.6.3 Total Revenues
> Graph 9.4 Cephalon> '> s Total Revenue 1999-2002
> 9.6.4 Total Operating Expenses
> Graph 9.5 Cephalon> '> s Total Operating Expenses 2000-2002
> 9.6.5 Research and Development Expenses
> Graph 9.6 Cephalon> '> s Research and Development Expenses 2001-2002
> 9.6.6 Assets
> Graph 9.7 Cephalon> '> s Total Assets 1999-2002
> 9.6.7 Net Income (Loss)
> Graph 9.8 Cephalon> '> s Net Income (Loss) 1999-2002
> 9.6.8 Stockholders' Equity
> Graph 9.9 Cephalon> '> s Stockholders> '> Equity 1999-2002
> 9.6.9 Earnings/Loss per Share
> 9.7 Prescription Drug Products in the Portfolio
> Table 9.1 Cephalon> '> s Key Products on European and American Markets
> 9.8 Cephalon's Key Money-Making Products
> 9.8.1 Provigil
> Graph 9.10 Cephalon> '> s Sales of Provigil 2000-2002
> 9.8.2 Actiq
> Graph 9.11 Cephalon> '> s Sales of Actiq 2000-2002
> 9.8.3 Gabitril
> Graph 9.12 Cephalon> '> s Sales of Gabitril 2000-2002
> 9.9 The CIMA Labs Merger
> 9.10 Research and Development
> Table 9.2 Cephalon> '> s Pharmaceutical Pipeline
> 9.10.1 Highlights
> 9.11 Reasons for Success
>
> 10 Gilead
> 10.1 Overview of Business
> 10.2 Corporate History Timeline
> 10.3 Employees
> 10.4 Headquarters and Year Established
> 10.5 U.S. Exchange Ticker Symbol
> 10.6 Historical Stock Prices
> Graph 10.1 Gilead> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 10.7 Key Financial Information>
> 10.7.1 Product Sales
> Graph 10.2 Gilead> '> s Product Sales 2000-2002
> 10.7.2 Royalty and Contract Revenue
> Graph 10.3 Gilead> '> s Royalty and Contract Revenue 2000-2002
> 10.7.3 Total Revenues
> Graph 10.4 Gilead> '> s Total Revenues
> 10.7.4 Total Operating Expenses
> Graph 10.5 Gilead> '> s Total Operating Expenses
> 10.7.5 Research and Development Expenses
> Graph 10.6 Gilead> '> s Research and Development Expenses
> 10.7.6 Assets
> Graph 10.7 Gilead> '> s Total Current Assets 2001-2002
> 10.7.7 Net Income (Loss)
> Graph 10.8 Gilead> '> s Net Income (Loss) 2000-2002
> 10.7.8 Stockholders' Equity
> Graph 10.9 Gilead> '> s Total Stockholders> '> Equity 2001-2002
> 10.7.9 Earnings/Loss per Share
> Graph 10.10 Gilead> '> s Net Income (Loss) per Share 2000-2002
> 10.8 Leading Prescription Drug Products in the Portfolio
> 10.8.1 Viread
> Graph 10.11 Gilead> '> s Sales of Viread 2001-2002
> 10.8.2 AmBisome
> Graph 10.12 Gilead> '> s Sales of AmBisome 2001-2002
> 10.9 Gilead's Other Products
> 10.9.1 Hepsera
> 10.9.2 Emtriva
> 10.9.3 Tamiflu
> 10.9.4 Vistide
> 10.9.5 DaunoXome
> 10.10 Joint Ventures/Alliances
> 10.11 Research and Development
> Table 10.1 Gilead> '> s Pharmaceutical Pipeline
> 10.11.1 Highlights
> 10.12 Reasons for Success
>
> 11 Millennium
> 11.1 Overview of Business
> 11.2 Corporate History Timeline
> 11.3 Employees
> 11.4 Headquarters and Year Established
> 11.5 U.S. Exchange Ticker Symbol
> 11.6 Historical Stock Prices
> Graph 11.1 Millennium> '> s Historical Stock Prices Jan 2003 to Nov 2003
> 11.7 Key Financial Information
> 11.7.1 Revenue Under Strategic Alliance
> Graph 11.2 Millennium> '> s Revenue Under Strategic Alliances 1998-2002
> 11.7.2 Total Revenues
> Graph 11.3 Millennium> '> s Total Revenues 1998-2002
> 11.7.3 Total Operating Expenses
> Graph 11.4 Millennium> '> s Total Costs and Expenses 1998-2002
> 11.7.4 Research and Development Expenses
> Graph 11.5 Millennium> '> s Research and Development Expenses 1998-2002
> 11.7.5 Assets
> Graph 11.6 Millennium> '> s Total Assets 1998-2002
> 11.7.6 Net Income (Loss)
> Graph 11.7 Millennium> '> s Net Income (Loss) 1998-2002
> 11.7.7 Stockholders' Equity
> Graph 11.8 Millennium> '> s Stockholders> '> Equity 1998-2002
> 11.7.8 Earnings/Loss per Share
> Graph 11.9 Millennium> '> s Total Income (Loss) per Share 1998-2002
> 11.8 Millennium's Key Businesses
> 11.8.1 Cardiovascular Diseases
> 11.8.2 Oncology
> 11.8.3 Inflammatory Disease
> 11.9 Integrilin: Millennium's First Major Product
> 11.9.1 Revenues
> 11.10 Velcade: New to the Cancer Market
> 11.11 Joint Ventures/Alliances
> 11.12 Research and Development
> Table 11.1 Millennium> '> s Cardiovascular Pipeline
> Table 11.2 Millennium> '> s Oncology Pipeline
> Table 11.3 Millennium> '> s Inflammatory Pipeline
> 11.12.1 Highlights
> 11.13 Reasons for Success
>
> -PRICING-
>
> Individual report pricing - single user copies of this report are available for only GBP£1499
> Report pricing - departmental copies (this entitles up to 5 individual users in your department) of this report are available for only GBP£2999
> Allow your whole company to have access to this information for only GBP£4499. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf.
> Carriage is via Fedex:
> USA - GBP£19.00; ASIA - GBP£25.00; Australia & NZ - GBP£25.00; EU GBP£23.00; Rest of Europe GBP£27.00
> UK is sent next day delivery through Royal Mail.
> -ORDERING-
> To order simply contact John Dennis mailto:john.dennis:-:visiongain.com
> Should you have any questions or should you want to buy a copy please let me know.
>
> Kind regards
>
> John Dennis
> Account Manager
> Visiongain Publishing
> tel: +44 (0) 208 767 6711
> fax: +44 (0) 208 767 5001
> mailto:john.dennis{=}visiongain.com
>
>
>
>
>
>
>
>
>
>
> visiongain produce a range of timely business information material, if you wish to receive information of new products, simply reply to this email with ' New Products info' in the subject box.>
>
>
>
>
>
>
>
>
> By replying to this e-mail submitting your order for this product you have agreed without limitation or qualification to be bound by and to comply with these Terms and Conditions. You agree that you will not fail to complete any transaction after submitting an order to purchase a product or submit any order to purchase a product where you do not intend to complete the transaction. You expressly acknowledge and agree that visiongain Ltd can withhold any product as a result of non-payment within the agreed credit terms of 30 days. Management Reports will only be sent on receipt of payment. Confirm any cancellations, prior to payment, in writing within one week and receive a refund less a 10% + VAT service charge. Regrettably, no refunds can be made for cancellations after one week.
>
> To unsubscribe please reply with unsubscribe in the subject line.
>
> Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
>
Received on 2004-10-05 - 13:03 GMT